This Monday, Bio-Thera Solutions and Dr. Reddy’s Laboratories SA announced that they had entered into commercialization and licensing agreements for proposed ustekinumab and golimumab ...

If you buy something via one of our links, we may earn a commission. The Nike KD Trey 5 X is on sale for $51, a 49% discount from its normal price of $100. These stylish and supportive basketball ...

With another inflammatory bowel disease (IBD) approval in the bag for Tremfya, Johnson & Johnson continues to make good on the succession plan for its declining autoimmune blockbuster Stelara.

During last night's win over the Bucks, Durant debuted the Nike KD 18 in the "El Valle" colorway. The mesmerizing colorway sported a purple upper, black accents, and hints of orange and teal.

This approval for Crohn’s disease may make Tremfya a direct competitor with Stelara. Perspective from Edward V. Loftus Jr., MD The FDA has approved Tremfya as the “first and only ...

Kyndryl Holdings, Inc. operates as a technology services company and IT infrastructure services provider worldwide. The company offers cloud services; core enterprise and zCloud services ...

Johnson & Johnson’s inflammatory disease drug Stelara has been approved in Europe for ulcerative colitis (UC), a new use for the multibillion dollar blockbuster. The European Commission cleared ...

No significant differences in the risk of myocardial infarction, ischemic stroke, or cardiovascular-related death were observed in patients with psoriasis or psoriatic arthritis initiating treatment ...

J&J has said it will now need upfront payment in full for its anticoagulant Xarelto (rivaroxaban) and immunology therapy Stelara (ustekinumab), with a rebate paid later, rather than the previous ...

While Bio-Thera’s BAT2206 is a proposed biosimilar of Stelara, BAT2506 is a proposed biosimilar of Simponi developed by Bio-Thera, a commercial-stage biopharmaceutical company that is developing ...

The label expansion could help J&J establish Tremfya as a successor to Stelara, which is now facing a growing biosimilar challenge. The FDA signed off on the use of Johnson & Johnson’s Tremfya ...